Targeting Ly6G+ neutrophil populations, using a small-molecule CXCR2 inhibitor, an ALK5 inhibitor, a TGFβ ligand-trap, or anti-Ly6G antibodies, attracted cytotoxic CD4+ and CD8+ T cells to the pre-metastatic niche and markedly reduced metastasis, providing new paths to therapy, albeit without impacting primary tumour burden [384]. The gene discussed is TGFB1; the disease is neoplasm.